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ABSTRACT
Objective: The effect of alpha-lipoic acid on blood pressure was investigated many times in chronic studies, but there are no studies on the 
effect of this compound after a single administration. Alpha-lipoic acid is a drug used in diabetic neuropathy, often in obese patients, to treat 
hypertension. Therefore, knowledge of the potential antihypertensive effect of alpha-lipoic acid even after a single dose and possibly too much 
pressure reduction is interesting and useful.
Methods: The mechanism of the hypotensive effect of alpha-lipoic acid was examined in normotensive rats in vivo after a single intraperito-
neal administration, blood pressure in the left carotid artery of the rats was measured prior to the administration of the compounds (alpha- 
lipoic acid and/or glibenclamide) and 80 min thereafter.
Results: Alpha-lipoic acid at a dosage of 50 mg/kg b.w. i.p. significantly decreased the blood pressure from the 50th min after drug administra-
tion. This cardiovascular effect of this compound was reversed by glibenclamide, a selective KATP blocker. Glibenclamide alone at this dose did 
not significantly affect the blood pressure. Statistical significance was evaluated using two-way ANOVA.
Conclusion: This suggests that alpha-lipoic acid affects ATP-dependent potassium channels. It is possible that this is an indirect effect of 
hydrogen sulfide because alpha-lipoic acid can increase its concentration. The results obtained in this study are very important because the 
patients taking alpha-lipoic acid may be treated for co-existing hypertension. Therefore, the possibility of blood pressure lowering by alpha-
lipoic acid should be taken into account, although it does not lead to excessive orthostatic hypotension. (Anatol J Cardiol 2016; 16: 306-9)
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Introduction
Alpha-lipoic acid has gained considerable interest as an 
antioxidant. It is readily absorbed from the diet, transported to 
tissues, and taken up by cells, where a large proportion of it is 
rapidly converted to its reduced form, dihydrolipoic acid (1). It 
cooperates with rhodanese in the sulfane sulfur metabolism and 
hydrogen sulfide (H2S) release. Sulfane sulfur is an essential 
storage form of H2S in the body (2, 3). Therefore, some of the 
effects observed after alpha-lipoic acid administration can be 
associated with the action of H2S.
In the cardiovascular system, endogenous H2S has impor-
tant physiological effects including vascular tone regulation (4). 
H2S induces hypotension in vivo (5) and vasodilatation in vitro (6) 
by opening KATP channels in vascular smooth muscle cells (5-7). 
H2S is endogenously produced by the heart tissue as a physio-
logical regulator of cardiac function (8). Glibenclamide, a KATP 
channel antagonist, attenuates the hypotensive effect of H2S in 
vivo and vasodilatation in vitro (3, 7).
The effect of alpha-lipoic acid on blood pressure was investigat-
ed many times in chronic studies (8-12), but there are no studies on 
the effect of this compound after a single administration. Alpha-lipoic 
acid is a drug used in diabetic neuropathy and diabetes, which occurs 
frequently together with hypertension, especially in obese patients, to 
treat hypertension. Therefore, knowledge of the potential antihyper-
tensive effect of alpha-lipoic acid even after a single dose and pos-
sibly too much pressure reduction is interesting and useful. 
Methods
The mechanism of the hypotensive effect of alpha-lipoic acid 
was examined in normotensive rats in vivo after a single intra-
peritoneal administration. 
The experiments were conducted on male Wistar rats 
(weight, 180–250 g). The animals were housed in plastic cages in 
a room at a constant temperature of 20±2°C with a natural light–
dark cycle. They had free access to a standard pellet diet and 
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water. Groups consisted of the following number of animals: 
group 1, n=7; group 2, n=7; group 3, n=6; group 4, n=8.
The rats in the groups were treated as follows:
Group 1: alpha-lipoic acid at a dosage of 50 mg/kg b.w., 
i.p., suspended in 1% Tween 80.
Group 2: glibenclamide at a dosage of 50 mg/kg b.w., i.p., 
suspended in 1% Tween 80.
Group 3: glibenclamide at a dosage of 50 mg/kg b.w., i.p. 30 
min before alpha-lipoic acid at a dosage of 50 mg/kg b.w., i.p.
Group 4: 0.25 mL of 1% Tween 80-control group. 
All experiments were conducted according to the guide-
lines of the Animal Use and Care Committee of the Jagiellonian 
University (No.: 96/2011, date: 09.21.2011). The entire surgery 
was performed under thiopental anesthesia, and all efforts 
were made to minimize suffering. 
The rats were anesthetized with thiopental (70 mg/kg) by 
an intraperitoneal injection. The left carotid artery was can-
nulated with a polyethylene tubing filled with heparin solution 
in saline to facilitate pressure measurements using the 
Datamax apparatus (Columbus Instruments, Ohio). Blood pres-
sure was measured prior to the administration of the com-
pounds (time 0 min-control pressure) and 80 min thereafter.
Statistical analysis
The results of the blood pressure measurements are pre-
sented as the means±S.E.M., and statistical significance of 
the differences was evaluated using a two-way ANOVA, 
Bonferroni’s multiple comparison test (four groups and ten 
factors). The differences were considered statistically sig-
nificant when p<0.05.
Results
Alpha-lipoic acid intraperitoneally administered at a dosage of 
50 mg/kg of b.w significantly lowered blood pressure 50 min after 
the administration to rats [systolic F(10,278)=2.828, p=0.0023; dia-
stolic F(10.268)=3.689, p=0.0001]. All animals survived the experi-
ence. There were no complications with the surgery. Glibenclamide 
(50 mg/kg) intraperitoneally administered 30 min before alpha-
lipoic acid inhibited its in all the time measuring points, there was 
no statistically significant difference between the pressure indi-
cated between the glibenclamide-treated groups and the control 
group (p>0.05). The results are shown in Figure 1. Table 1 shows 
the percentage of pressure drops in each group.
Discussion
In this study we demonstrated a significant effect of alpha-
lipoic acid at a dosage of 50 mg/kg of b.w. on blood pressure in 
rats after one intraperitoneal administration. Glibenclamide, a 
KATP channel antagonist, attenuated this effect.
There are many papers in literature describing the impact of 
the chronic administration of alpha-lipoic acid on blood pres-
sure pointing to its hypotensive effect after repeated administra-
tion or prevention of the development of hypertension (8-12). 
However, there is no described effect of alpha-lipoic acid on 
blood pressure after a single administration. In the present 
study, alpha-lipoic acid was intraperitoneally administered to 
rats at a dosage of 50 mg/kg of b.w. It was demonstrated that this 
dosage significantly reduced blood pressure, but the effect was 
visible beginning from the 50th minute after the administration. 
Typically, the hypotensive effect after intraperitoneal treatment 
with a blood pressure-lowering compound is faster. There may 
be various reasons explaining why the hypotensive effect was 
not manifested until 50th minute after the administration, includ-
ing poor absorption of the compound after the intraperitoneal 
administration. Alpha-lipoic acid may be subject to changes or 
metabolized before its activity may be expressed or it may 
induce the formation of blood pressure reducing agents.
We also performed studies on the impact of the co-adminis-
tration of glibenclamide, an ATP-dependent potassium channel 
inhibitor because it is known that the KATP channel opening is 
involved in the integrated vasodilator response to H2S in vivo in 
rats and that this effect is abrogated by the glibenclamide-
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Figure 1. a, b. The effect of alpha-lipoic acid, glibenclamide, and both 
compounds on blood pressure after a single administration
The data represent systolic (a) and diastolic (b) blood pressure, means±S.E.M., after the 
administration of alpha-lipoic acid (50 mg/kg b.w., intraperitoneal injection)-LA group, or 
glibenclamide (50 mg/kg b.w., intraperitoneal injection)–G group, or alpha-lipoic acid (50 mg/
kg b.w., intraperitoneal injection) plus glibenclamide (50 mg/kg b.w., intraperitoneal 
injection)-LA+G group, or 1% Tween 80 (0.25 mL, intraperitoneal injection)-control group; 
*significant LA group vs. control group in each time point: *P<0.05, **P<0.01 (two-way 




induced blockade of the KATP channel (13).
Other studies have shown that glibenclamide abolishes the 
decongestant action of alpha-lipoic acid, suggesting that ATP-
dependent potassium channels are involved in this action 
(14, 15) and that this effect could be associated with the forma-
tion of H2S.
There are reports indicating that the anti-inflammatory effect 
of alpha-lipoic acid may be associated with increased sulfane 
sulfur levels and H2S release (16). Additionally, other thiols such 
as L-cysteine or glutathione may be sulfane sulfur donors 
(17, 18) and may increase the levels of H2S (17). It has been 
demonstrated that H2S is released from bound sulfur in the pres-
ence of physiological concentrations of glutathione and cyste-
ine under slightly alkaline conditions. Extracellular potassium 
increases the intracellular pH to the level that supports H2S 
release (17).
Therapy for cardiovascular system diseases utilizes the 
cardioprotective properties of compounds such as nicorandil 
(coronary heart disease), narcotic analgesics (post-myocardi-
al infarction medication, cardioprotective effect), and adenos-
ine (arrhythmias) for opening ATP-dependent potassium chan-
nels. Nicorandil opens KATP channels, thereby dilating periph-
eral resistance and coronary arterioles. It may cause a 
decrease in preload and blood pressure. Therefore, the results 
are very interesting, suggesting that alpha-lipoic acid, a drug 
used in diabetic neuropathy, may have cardioprotective prop-
erties related to this mechanism.
Study limitations
The most important limitation of our study was the lack of 
detailed studies at the cellular level. 
Another very important limitation of our study was the dura-
tion of the experiment. 
Conclusion
This study suggests that the observed effect of alpha-lipoic 
acid on blood pressure is associated with increased levels of 
sulfane sulfur, opening of ATP-dependent potassium channels, 
and release of H2S.
The results obtained in this study are very important because 
the patients taking alpha-lipoic acid may be treated for co-
existing hypertension. Therefore, they must take into account the 
possibility of the blood pressure-lowering effect of alpha-lipoic 
acid that does not lead to excessive orthostatic hypotension.
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